ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VCEL Vericel Corporation

52.22
2.37 (4.75%)
After Hours
Last Updated: 22:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Vericel Corporation NASDAQ:VCEL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.37 4.75% 52.22 51.95 53.96 52.71 49.585 50.66 437,267 22:30:00

WallSt.net Airing All-New, Exclusive Audio Interviews With CVAS and ASTM

19/05/2005 1:00pm

PR Newswire (US)


Vericel (NASDAQ:VCEL)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Vericel Charts.
WallSt.net Airing All-New, Exclusive Audio Interviews With CVAS and ASTM NEW YORK, May 19 /PRNewswire/ -- Sayan Navaratnam, CEO of Creative Vistas, Inc. (OTC:CVAS) (BULLETIN BOARD: CVAS) recently granted Wall Street Network an exclusive audio interview profiling the company. Interview highlights include detailed discussions on the following topics: -- Feedback from a recent demonstration of the company's streaming video capabilities to the FBI, EPA and other governmental agencies -- Technological edge over competition -- Financials -- Possibility of the company's deal with BMW extending into the U.S. -- Management bios -- Upcoming milestones To hear the interview in its entirety, and to read an in-depth report on the company, visit http://wallst.net/superstock/CVAS/cvas.html . Douglas Armstrong, PhD, Chairman and CEO of Aastrom Biosciences, Inc. (NASDAQ:ASTM) recently granted Wall Street Network an all-new exclusive audio interview profiling the company. Interview highlights include discussions on the following topics: -- new results from the company's feasibility study in Spain -- why the company's stem-cells are "non-controversial" -- financials -- timeline for U.S. clinical trials -- recently granted expansion in U.S. clinical trials -- upcoming clinical milestones To hear the interview in its entirety, visit http://www.wallst.net/ . The interview can be accessed by locating the company's ticker symbol under the exchange on which it trades on the left hand column of the homepage, or by entering the company's ticker symbol in the Audio Search window. About Wall Street Network Wall Street Network is owned and licensed by Wall Street Direct, Inc. All material herein was prepared by Digital Wall Street, Inc., a multimedia provider of original, insightful commentary and news from North America's leading publicly traded companies giving a direct link to the management of today's fastest-growing companies through encompassing executive interviews and sector seminars. The company provides a free service to consumers, and a paid, premium monthly subscription to its members. Digital Wall Street, Inc. has received six thousand five hundred dollars from CVAS for press and advertising services, and six thousand five hundred free trading shares of CVAS from a third party for press and advertising services. For a complete list of our business relationships, visit http://www.wallst.net/disclaimer.asp . Contact: Nick Iyer Digital Wall Street, Inc. 800-4-WALL-ST DATASOURCE: Wall Street Network CONTACT: Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST Web site: http://www.wallst.net/disclaimer.asp Web site: http://wallst.net/superstock/CVAS/cvas.html Web site: http://www.wallst.net/

Copyright

1 Year Vericel Chart

1 Year Vericel Chart

1 Month Vericel Chart

1 Month Vericel Chart

Your Recent History

Delayed Upgrade Clock